Day 1 :
Kugelmeiers AG, Switzerland
Keynote: How laws of nature should guide the development of 3D cell culture for regenerative medicine
Time : 09:15-10:00
Patrick Kugelmeier is the Founder and Director of Kugelmeiers AG, Zurich Switzerland. He studied medicine and did his medical thesis on islet transplantation for the treatment of diabetes. The joy of research led to an MD-PhD program for the early differentiation of stem cells. After the MD-PhD program, he did his clinical training in visceral and transplant surgery followed by trauma surgery.
We are at a tipping point where nature is revealing us top secrets of life. We can reveal them when we look at life how it is really in 3D. 3D cell culture systems reflecting real-life processes thus provide not only sound scientific data but also enable regenerative medicine with stem cells. Almost every life begins with cell clusters. 3D cell clusters are therefore ideal scientific models that offer additional therapeutic options. But for full functionality, clusters need to be size controlled in a physiological, cozy environment. Unfortunately, current technology is limited to either quality or scalability and therefore many desired applications are not possible. Because of this unmet medical need, we, therefore, developed the spherical plate 5D enabling the full translation from lab to clinics with freely scalable, size-controlled spheroids in clinical grade quality. A human multi-center trial for the treatment of diabetes is beginning in 2019.
CelluGen Biotech Pvt. Ltd., India
Time : 10:00-10:45
Falk Heinrichsohn has a Business Administration background and is Passionate about Health and Wellness. After various positions at Merck ́s Headquarter in Germany, he started his global journey as General Manager, developing and implementing strategizing business structures in ten countries. In 2006, he established a foundation, to sponsor patients with unmet medical need. After his retirement from the corporate world, he has contributed in developing various alternative health and wellness companies along with stem cell clinics. He is a Member of the International Consortium for Cell Therapy and Immunotherapy in Europe. Since 2016, he has been working closely with Lalit Jaiswal, Founder, Director of CelluGen Biotech; a stem cell research company based in India. Together with the amalgamation of technology, knowledge, and expertise, they have introduced to the world the innovative concept of corrective utilization of cord blood in the private cord banking sector.
Background: Stem cells from cord blood (CB) are an approved therapeutic source for various haematological disorders. Its storage became popular in America during the 1990s and developed globally as an alternative to bone marrow transplant. In America, private cord blood banking is stagnant, in Europe the market is declining, while Asia is expanding via increasing birth rate.
Therapeutic Value of Privately Stored Cord Blood: Discussions have emerged regarding the utility of privately stored CB. Haematologists consider that the promoted therapeutic self-use is much limited. It is scientifically proven that about 90% of treatable blood related disorders in children are hereditary/genetic and not acquired; therefore, autologous use is not viable.
Private Cord Blood Banking–Redefined: CelluGen Biotech, India developed after years of R&D, an innovative cord blood pool banking concept, where high CB volumes are collected, analyzed, processed and cryopreserved after human leukocyte antigen (HLA) typing to ensure effective allogeneic utilization of the banked CB by its members. India has a high birth rate and a high diseases burden of hematopoietic disorders. The limited availability of a bone marrow match and absence of compatible cord blood units in public banks, inspired CelluGen to introduce “Cellulife” an allogeneic storage model, where on request of a parent, who did not store the CB unit at birth, CelluGen will procure it from a donor, process and store it for a fee in the private CB bank which entitles the parent to protect their family as a member of the private pool banking.
Conclusion: Cord blood is a valuable alternative of bone marrow and cryopreserving umbilical cord blood (UCB) stem cells is a valid concept if expanded to a pool banking structure. This concept may also reduce the dependence on donor bone marrow through a timely supply of UCB units for blood-related disorders.